Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Rosetta's miRNA-Based Cancer Tests Break Into European Market through Distribution Deal with AXA

AXA will supply tests in Italy, and Rosetta anticipates availability in other countries before the end of the year.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

The Price of BRCA Testing

Is getting a genetic test worth the multi-thousand dollar price?

Suggest a Poll